Uncategorized
Prostate cancer therapy gets MHRA marketing authorisation

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to a treatment for metastatic hormone-sensitive prostate cancer (mHSPC).
Akeega (niraparib and abiraterone acetate), developed by Johnson & Johnson, has been granted the authorisation as part of a combination regimen with prednisone or prednisolone and andogren deprivation therapy (ADT).
The authorisation paves the way for adult patients in the UK with BRCA1/2-mutated mHSPC to receive a new treatment on the NHS.
Results from the Phase III AMPLITUDE trial showed that, in 696 patients with mHSPC, niraparib and abiraterone with prednisone significantly prolonged the time to symptomatic progression, prolonged overall survival, and reduced the risk of death by 20%.
“This announcement represents an important step forward for men in the UK with BRCA1/2-mutated mHSPC,” said Dr John Fleming, Country Medical Director, Johnson & Johnson Innovative Medicine UK.
“These patients haven’t historically had a treatment option tailored to the underlying biology of their disease. This authorisation expands the use of precision medicine to an earlier stage of BRCA1/2-mutated prostate cancer and provides a new treatment option that enables care to be tailored to the underlying biology of the disease.
Figures show prostate cancer is the most diagnosed cancer in men in the UK, with about 64,000 men diagnosed every year and around 20% presenting with metastatic disease. The majority of cases are hormone-sensitive, with between 8% and 12% of patients with mHSPC having BRCA1/2 gene alterations.
The post Prostate cancer therapy gets MHRA marketing authorisation appeared first on Drug Discovery World (DDW).